XBiotech Inc.(XBIT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 40 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
XBIT Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for XBiotech Inc. (XBIT), a Healthcare sector company. XBIT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 40 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q2 2026), XBiotech Inc. reports net income of $-6.7M, free cash flow of $-4.5M. Top institutional holders of XBIT by reported 13-F value include BlackRock, GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. XBIT trades on the Nasdaq exchange and files with the SEC under CIK 1626878. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XBIT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for XBiotech Inc. directly from SEC EDGAR. XBiotech Inc.'s 13F Pro composite quality score has ranged between 7 and 47 since 2022, currently 22.1 — an improving long-term trajectory across 9 quarterly and live scoring snapshots.
Net Income
Q2 2026
$-6.7M
Free Cash Flow
Q2 2026
$-4.5M
ROIC
Q2 2026
-19.1%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-18.2% YoYOperating Income
-31.1% YoYEPS (Diluted)
-18.3% YoYTotal Assets
-24.6% YoYOp. Cash Flow
-28.9% YoYFree Cash Flow
-24.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 -100.0% | $4.0M -78.2% | $18.4M -58.2% | $44.0M |
| Net Income | $-45.5M -18.2% | $-38.5M -56.9% | $-24.6M +25.4% | $-32.9M -88.9% | $-17.4M -55.2% | $-11.2M |
| Operating Income | $-55.7M -31.1% | $-42.5M -13.2% | $-37.5M -8.8% | $-34.5M -37.5% | $-25.1M -37.2% | $-18.3M |
| EPS (Diluted) | $-1.49 -18.3% | $-1.26 -55.6% | $-0.81 +25.0% | $-1.08 -86.2% | $-0.58 -61.1% | $-0.36 |
| Total Assets | $150.1M -24.6% | $199.1M -12.1% | $226.6M -7.9% | $246.1M -10.6% | $275.2M -22.2% | $353.7M |
| Operating Cash Flow | $-39.9M -28.9% | $-31.0M -65.4% | $-18.7M -26.3% | $-14.8M -121.3% | $69.4M +206.6% | $-65.1M |
| Free Cash Flow | $-40.2M -24.6% | $-32.3M -69.1% | $-19.1M -23.9% | $-15.4M -123.4% | $65.9M +195.7% | $-68.9M |
Get alerted when XBIT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for XBiotech Inc. including:
Top Institutional Holders of XBIT
BlackRock, Inc.
$738.6K321,146 shGEODE CAPITAL MANAGEMENT, LLC
$492.8K214,116 shVANGUARD CAPITAL MANAGEMENT LLC
$460.4K200,182 shRBF Capital, LLC
$456.6K198,501 shMORGAN STANLEY
$340.1K147,880 shBRIDGEWAY CAPITAL MANAGEMENT, LLC
$226.4K98,447 shVANGUARD FIDUCIARY TRUST CO
$212.4K92,365 shMILLENNIUM MANAGEMENT LLC
$182.5K79,330 shJANE STREET GROUP, LLC
$171.8K74,700 shSTATE STREET CORP
$167.9K73,006 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $738.6K | 321,146 |
| GEODE CAPITAL MANAGEMENT, LLC | $492.8K | 214,116 |
| VANGUARD CAPITAL MANAGEMENT LLC | $460.4K | 200,182 |
| RBF Capital, LLC | $456.6K | 198,501 |
| MORGAN STANLEY | $340.1K | 147,880 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $226.4K | 98,447 |
| VANGUARD FIDUCIARY TRUST CO | $212.4K | 92,365 |
| MILLENNIUM MANAGEMENT LLC | $182.5K | 79,330 |
| JANE STREET GROUP, LLC | $171.8K | 74,700 |
| STATE STREET CORP | $167.9K | 73,006 |
More Healthcare Companies
View all Healthcare →Put XBIT on your watchlist
Track score changes the day XBiotech Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is XBIT a good stock to buy?
13F Pro's AI-powered analysis of XBiotech Inc. (XBIT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XBIT are available on the XBIT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. XBIT is classified as a small company.
Which hedge funds own XBIT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XBIT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of XBiotech Inc.'s investment landscape.